Show simple item record

dc.contributor.authorNath, Karthik
dc.contributor.authorReyaldeen, Reza
dc.contributor.authorPalamuthusingam, Dharmenaan
dc.date.accessioned2019-12-06T02:22:34Z
dc.date.available2019-12-06T02:22:34Z
dc.date.issued2019
dc.identifier.issn1444-0903en_US
dc.identifier.doi10.1111/imj.14452en_US
dc.identifier.urihttp://hdl.handle.net/10072/389575
dc.description.abstractWe congratulate Leitinger et al.1 and co‐authors for their comprehensive review on the use of proton‐pump inhibitors (PPI) in patients with malignant haematological conditions. The authors highlight the high prophylactic and often extended use of PPI in patients receiving treatment for multiple myeloma, lymphoma and recipients of autologous haemopoietic stem cell transplantation. In those with multiple myeloma or lymphoma there was no strong indication for the initiation of PPI in more than half the patients studied. Furthermore, therapy was typically continued for a protracted duration, sometimes indefinitely despite no indication for therapy. Studies involving the general population from the United States and the United Kingdom have also reported up to 70% of PPI prescription without indication.2, 3 The authors have also highlighted the paucity of robust evidence on the indications for prophylaxis in those patients receiving glucocorticoid therapy. Their national survey demonstrated high variability in clinical practice and an overall lack of institutional protocols for the use of PPI therapy in this setting.en_US
dc.languageEnglishen_US
dc.publisherWileyen_US
dc.publisher.placeAustralia
dc.relation.ispartofpagefrom1337en_US
dc.relation.ispartofpageto1337en_US
dc.relation.ispartofissue10en_US
dc.relation.ispartofjournalInternal Medicine Journalen_US
dc.relation.ispartofvolume49en_US
dc.subject.fieldofresearchClinical Sciencesen_US
dc.subject.fieldofresearchPublic Health and Health Servicesen_US
dc.subject.fieldofresearchcode1103en_US
dc.subject.fieldofresearchcode1117en_US
dc.subject.keywordsLife Sciences & Biomedicineen_US
dc.subject.keywordsGeneral & Internal Medicineen_US
dc.subject.keywordsScience & Technologyen_US
dc.titleProton-pump inhibitor overuse: a cautionary tale in misguided benefit (Letter)en_US
dc.typeJournal articleen_US
dc.type.descriptionC2 - Articles (Other)en_US
dcterms.bibliographicCitationNath, K; Reyaldeen, R; Palamuthusingam, D, Proton-pump inhibitor overuse: a cautionary tale in misguided benefit, Internal Medicine Journal, 2019, 49 (10), pp. 1337-1337en_US
dcterms.dateAccepted2019-07-08
dc.date.updated2019-12-02T00:26:58Z
dc.description.versionPost-printen_US
gro.rights.copyright© 2019 Royal Australasian College of Physicians. This is the peer reviewed version of the following article: Proton-pump inhibitor overuse: a cautionary tale in misguided benefit, Internal Medicine Journal, Vol. 49, Iss. 10, October 2019, Pages 1337-1337, which has been published in final form at 10.1111/imj.14452. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving (http://olabout.wiley.com/WileyCDA/Section/id-828039.html)en_US
gro.hasfulltextFull Text
gro.griffith.authorPalamuthusingam, Dharmenaan


Files in this item

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record